Cognito Therapeutics

Cognito Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceswww.cognitotx.com

Last Round

Series C

Mar 5, 2026

Total Funding Raised

$419.2M

Momentum Score

50 /100

Company Overview

Cognito Therapeutics is a digital health company that develops disease-modifying therapies aimed at treating neurodegenerative disorders by utilizing induced brain wave oscillations to reactivate the brain's immune system and reduce key Alzheimer's disease markers such as amyloid plaques and tau tangles.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Biotechnology, Health IoT

Business Model

B2B2C

Customer Profile

Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

digital therapeuticsprescription digital therapeuticPDTAlzheimer's therapyneuromodulationneurotechnologygamma frequency stimulationneuro devicenon-invasive therapysensory stimulationgamma therapydisease-modifying therapy40Hz stimulationat-home medical devicebrain healthFDA breakthrough device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cognito Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cognito Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CMar 5, 2026
Series CApr 1, 2025
Series BJul 2, 2024
Series B ExtensionFeb 1, 2024
Series BMar 22, 2023

Key People

Founding team and executive leadership

Angela Silva

Office Of The CEO Executive Operations

Executive Team

Christian Howell

Chief Executive Officer

Executive Team

Cognito Therapeutics Investors

Notable investors and investment history

InvestorRounds
New Vintage PartnersSeries C
IAG Capital PartnersSeries B, Series C
Starbloom CapitalSeries B, Series B Extension, Series C
FoundersX VenturesSeries B Extension, Series B
Morningside VenturesSeries B, Series C, Series A
WS Investment CompanySeries B
Alzheimer's Drug Discovery FoundationSeries B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2026

    Topline data from the HOPE pivotal study anticipated in summer 2026.

  • Apr 7, 2026

    Translating scientific findings from MIT into therapeutic approaches.

Cognito Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cognito Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cognito Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range59
Year Founded2016
Last FundingMar 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.